Literature DB >> 33441413

Uncovering the Harms of Treating Clostridioides difficile Colonization.

Christopher R Polage1,2, Nicholas A Turner3.   

Abstract

Patients with toxin-negative Clostridioides difficile-positive diarrhea are often treated with oral vancomycin with the assumption that treatment is more beneficial than harmful. However, this hypothesis has never been formally tested, and recent studies suggest that most such patients recover quickly without treatment and can be colonized rather than infected. Fishbein et al. conducted a prospective, placebo-controlled randomized trial to systematically evaluate the effects, risks, and benefits of oral vancomycin in these patients (S. R. S. Fishbein, T. Hink, K. A. Reske, C. Cass, et al., mSphere 6:e00936-20, 2020, https://doi.org/10.1128/mSphere.00936-20). Although small, the results are intriguing and suggest the adverse antibiotic-induced effects of vancomycin outweigh the clinical benefit when colonization is more likely than disease.
Copyright © 2021 Polage and Turner.

Entities:  

Keywords:  Clostridioides difficile; clinical trials; vancomycin

Year:  2021        PMID: 33441413      PMCID: PMC7845611          DOI: 10.1128/mSphere.01296-20

Source DB:  PubMed          Journal:  mSphere        ISSN: 2379-5042            Impact factor:   4.389


  21 in total

1.  European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection.

Authors:  M J T Crobach; T Planche; C Eckert; F Barbut; E M Terveer; O M Dekkers; M H Wilcox; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2016-07-25       Impact factor: 8.067

2.  Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses.

Authors:  Daniel A Caroff; John T Menchaca; Zilu Zhang; Chanu Rhee; Michael S Calderwood; David W Kubiak; Deborah S Yokoe; Michael Klompas
Journal:  Infect Control Hosp Epidemiol       Date:  2019-04-29       Impact factor: 3.254

3.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

4.  Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity.

Authors:  Anne Vrieze; Carolien Out; Susana Fuentes; Lisanne Jonker; Isaie Reuling; Ruud S Kootte; Els van Nood; Frits Holleman; Max Knaapen; Johannes A Romijn; Maarten R Soeters; Ellen E Blaak; Geesje M Dallinga-Thie; Dorien Reijnders; Mariëtte T Ackermans; Mireille J Serlie; Filip K Knop; Jenst J Holst; Claude van der Ley; Ido P Kema; Erwin G Zoetendal; Willem M de Vos; Joost B L Hoekstra; Erik S Stroes; Albert K Groen; Max Nieuwdorp
Journal:  J Hepatol       Date:  2013-12-06       Impact factor: 25.083

Review 5.  Antibiotics and Clostridium difficile.

Authors:  J Freeman; M H Wilcox
Journal:  Microbes Infect       Date:  1999-04       Impact factor: 2.700

6.  Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits.

Authors:  Katharina Brandl; George Plitas; Coralia N Mihu; Carles Ubeda; Ting Jia; Martin Fleisher; Bernd Schnabl; Ronald P DeMatteo; Eric G Pamer
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

7.  Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era.

Authors:  Christopher R Polage; Clare E Gyorke; Michael A Kennedy; Jhansi L Leslie; David L Chin; Susan Wang; Hien H Nguyen; Bin Huang; Yi-Wei Tang; Lenora W Lee; Kyoungmi Kim; Sandra Taylor; Patrick S Romano; Edward A Panacek; Parker B Goodell; Jay V Solnick; Stuart H Cohen
Journal:  JAMA Intern Med       Date:  2015-11       Impact factor: 21.873

Review 8.  Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis.

Authors:  Zain Kassam; Christine H Lee; Yuhong Yuan; Richard H Hunt
Journal:  Am J Gastroenterol       Date:  2013-03-19       Impact factor: 10.864

9.  Short- and long-term effects of oral vancomycin on the human intestinal microbiota.

Authors:  Sandrine Isaac; Jose U Scher; Ana Djukovic; Nuria Jiménez; Dan R Littman; Steven B Abramson; Eric G Pamer; Carles Ubeda
Journal:  J Antimicrob Chemother       Date:  2016-10-05       Impact factor: 5.790

10.  Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.

Authors:  Skye R S Fishbein; Tiffany Hink; Kimberly A Reske; Candice Cass; Emily Struttmann; Zainab Hassan Iqbal; Sondra Seiler; Jennie H Kwon; C A Burnham; Gautam Dantas; Erik R Dubberke
Journal:  mSphere       Date:  2021-01-13       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.